SG11201408539UA - Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof - Google Patents

Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof

Info

Publication number
SG11201408539UA
SG11201408539UA SG11201408539UA SG11201408539UA SG11201408539UA SG 11201408539U A SG11201408539U A SG 11201408539UA SG 11201408539U A SG11201408539U A SG 11201408539UA SG 11201408539U A SG11201408539U A SG 11201408539UA SG 11201408539U A SG11201408539U A SG 11201408539UA
Authority
SG
Singapore
Prior art keywords
urolithin
international
urolithins
lausanne
precursors
Prior art date
Application number
SG11201408539UA
Other languages
English (en)
Inventor
William Blanco-Bose
Bernard Schneider
Christopher L Rinsch
Laurent Mouchiroud
Dongryeol Ryu
Penelope Andreux
Johan Auwerx
Original Assignee
Amazentis Sa
Christopher L Rinsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amazentis Sa, Christopher L Rinsch filed Critical Amazentis Sa
Publication of SG11201408539UA publication Critical patent/SG11201408539UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
SG11201408539UA 2012-06-27 2013-06-27 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof SG11201408539UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261665137P 2012-06-27 2012-06-27
US201261712886P 2012-10-12 2012-10-12
US201361791137P 2013-03-15 2013-03-15
PCT/US2013/048310 WO2014004902A2 (en) 2012-06-27 2013-06-27 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof

Publications (1)

Publication Number Publication Date
SG11201408539UA true SG11201408539UA (en) 2015-01-29

Family

ID=48782652

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201408539UA SG11201408539UA (en) 2012-06-27 2013-06-27 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
SG10202106329TA SG10202106329TA (en) 2012-06-27 2013-06-27 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
SG10201610798QA SG10201610798QA (en) 2012-06-27 2013-06-27 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10202106329TA SG10202106329TA (en) 2012-06-27 2013-06-27 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
SG10201610798QA SG10201610798QA (en) 2012-06-27 2013-06-27 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof

Country Status (14)

Country Link
US (7) US11020373B2 (ko)
EP (2) EP4233858A1 (ko)
JP (4) JP6422163B2 (ko)
KR (4) KR20210128511A (ko)
CN (2) CN110934863A (ko)
AR (1) AR091604A1 (ko)
AU (5) AU2013284419A1 (ko)
BR (1) BR112014032809A8 (ko)
CA (2) CA2877718C (ko)
ES (1) ES2968368T3 (ko)
MX (3) MX2014016044A (ko)
PT (1) PT2866804T (ko)
SG (3) SG11201408539UA (ko)
WO (1) WO2014004902A2 (ko)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201408539UA (en) 2012-06-27 2015-01-29 Amazentis Sa Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
CA2895914C (en) * 2013-01-18 2023-06-20 Procell Sprl Urolithin b with testosterone, leucine and/or creatine for muscle growth
AU2014317857B2 (en) * 2013-09-09 2020-01-02 Natreon, Inc. Regulation of body weight gain by using dibenzo-alpha-pyrones
EP2862568A1 (en) * 2013-10-15 2015-04-22 Centre National de la Recherche Scientifique (CNRS) Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion
EP3087065B1 (en) 2013-12-23 2020-01-22 Amazentis SA Synthesis of urolithins
GB201323008D0 (en) 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
GB201413228D0 (en) 2014-07-25 2014-09-10 Nugerontix Ltd Polyphenol compositions
US20170367390A1 (en) * 2014-12-19 2017-12-28 Halo Life Science, Llc Use of ellagic acid dihydrate in food products and nutraceuticals
ES2902017T3 (es) * 2015-04-13 2022-03-24 Sumitomo Seika Chemicals Método de producción de ácidos benzoicos 2-halogenados
JP6740548B2 (ja) * 2015-05-15 2020-08-19 公立大学法人岡山県立大学 ウロリチン類を含有する育毛剤、及び、ウロリチン類を含有する５αレダクターゼ活性阻害剤
JP2017014154A (ja) * 2015-07-01 2017-01-19 公立大学法人岡山県立大学 ウロリチン類を含有するヒアルロン酸産生促進剤
JP6799767B2 (ja) * 2015-07-07 2020-12-16 公立大学法人岡山県立大学 ウロリチン類を含有するメラニン産生抑制剤
GB201515391D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
EP3393467B1 (en) * 2015-12-24 2020-07-01 Amazentis SA Compositions comprising nicotinamide riboside and a urolithin
JP6791478B2 (ja) * 2016-05-26 2020-11-25 株式会社ダイセル ウロリチン類を含有するアンジオテンシン変換酵素阻害剤
JP2017210444A (ja) * 2016-05-26 2017-11-30 株式会社ダイセル ウロリチン類を含有するリパーゼ阻害剤
EP3478091B1 (en) * 2016-06-29 2024-03-20 Halo Life Science, LLC Method of preparing a low odor dicholinium ellagate salt and other low odor organic salts of choline
US10774328B2 (en) 2016-07-11 2020-09-15 University Of North Texas Health Science Center At Fort Worth Treatment for glaucoma and other eye diseases
WO2018085419A1 (en) 2016-11-01 2018-05-11 Jian Feng Method of producing naive pluripotent stem cells
EP3354645A1 (en) 2017-01-26 2018-08-01 Patheon Austria GmbH & Co KG Process for preparing urolithins
WO2018162645A1 (en) 2017-03-08 2018-09-13 Amazentis Sa Skin treatment methods
WO2018162651A1 (en) 2017-03-08 2018-09-13 Amazentis Sa Methods for improving mitophagy in subjects
WO2018162650A1 (en) 2017-03-08 2018-09-13 Amazentis Sa Methods for improving mitophagy in subjects
JP2019097566A (ja) * 2017-12-07 2019-06-24 大正製薬株式会社 体内時計調整用組成物
JP7434155B2 (ja) * 2017-12-20 2024-02-20 ソシエテ・デ・プロデュイ・ネスレ・エス・アー オートファジーの誘導のためにオートファジー誘導因子と高タンパク質との組み合わせを使用する組成物及び方法
WO2019121855A1 (en) * 2017-12-20 2019-06-27 Societe Des Produits Nestle S.A. Compositions and methods using high protein for induction of autophagy
CA3089695A1 (en) * 2018-02-19 2019-08-22 Natreon, Inc. Synergistic combinations of urolithins a and b for improving cognitive capacity or cognitive function
WO2019163437A1 (ja) 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤
WO2019187918A1 (ja) * 2018-03-29 2019-10-03 国立大学法人 琉球大学 分化コントロール化合物を用いて造腫瘍性をもつおそれのある未分化ｉＰＳ細胞等の混入を除去する方法
WO2019211294A1 (en) 2018-04-30 2019-11-07 Amazentis Sa Urolithin a as immune enhancer
AU2019269401A1 (en) * 2018-05-15 2021-01-07 The Institute For Stem Cell Biology And Regenerative Medicine (Instem) Urolithin A and derivatives thereof for use in therapy
JP2021527048A (ja) * 2018-06-05 2021-10-11 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド 癌治療のためのアシル化カテキンポリフェノールおよびその使用方法
EP3801496A4 (en) 2018-06-05 2022-07-06 Flagship Pioneering Innovations V, Inc. ACTIVE AGENTS AND METHODS OF USE THEREOF FOR TREATING METABOLIC DISORDERS AND NAFLD
CN108676013B (zh) * 2018-06-25 2021-01-01 中国医学科学院医药生物技术研究所 具有自噬激活活性的黄醇酮类化合物、其制备方法及其制药应用
CN109316478A (zh) * 2018-11-06 2019-02-12 上海出入境检验检疫局动植物与食品检验检疫技术中心 一种尿石素a在制备抗衰老的药物、化妆品中的应用及药物、化妆品
CN113260360A (zh) * 2019-01-18 2021-08-13 雀巢产品有限公司 用于增加干细胞功能的试剂和方法
CN110066284B (zh) * 2019-02-01 2021-06-04 贵阳倍隆生物科技有限公司 一种一锅法合成鞣花酸的方法
CN110229167B (zh) * 2019-05-22 2020-11-24 珠海萱嘉君行健康产业发展有限公司 一种利用五倍子制备鞣花酸的方法、制得的鞣花酸及其应用
CN111995610A (zh) * 2019-05-27 2020-11-27 首都医科大学 一种尿石素类化合物用于治疗胶质母细胞瘤药物的应用
US20200397807A1 (en) * 2019-06-18 2020-12-24 MitoPower, LLC Nicotinyl riboside compounds and their uses
US20220184015A1 (en) * 2019-06-20 2022-06-16 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
GB201915191D0 (en) * 2019-10-21 2019-12-04 Floratek Gmbh Novel heterocyclic compounds
GB201916046D0 (en) 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
CN114760996A (zh) * 2019-11-27 2022-07-15 雀巢产品有限公司 与间接ampk活化剂化合物组合的直接ampk活化剂化合物、组合物、方法和其用途
US20230048350A1 (en) * 2019-11-27 2023-02-16 Societe Des Produits Nestle S.A. Benzocoumarin ampk activator compounds, compositions, methods and uses thereof
CN113018305A (zh) * 2019-12-24 2021-06-25 兰州大学 一种化合物在制备治疗阿尔兹海默症药物中的应用
JP2023520299A (ja) * 2020-02-20 2023-05-17 ザ ロイヤル インスティチューション フォー ジ アドヴァンスメント オブ ラーニング／マギル ユニヴァーシティ 抗がん有効性のための、及び免疫チェックポイント阻害剤に対する応答を増加させるための、カスタラギン又はその類似体の使用
US20240000753A1 (en) * 2020-07-17 2024-01-04 The Trustees Of Columbia University In The City Of New York Methods and compositions to increase lifespan and healthspan by mimicking the effects of time-restricted feeding
CN111983058B (zh) * 2020-07-30 2023-06-23 云南中医药大学 中药抗非酒精性脂肪肝活性物质的筛选方法
US20220071952A1 (en) * 2020-09-04 2022-03-10 Natreon, Inc. Methods of treating and preventing hepatotoxicity
CA3188397A1 (en) 2020-09-25 2022-03-31 Anupama Dattatreya Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
KR102623664B1 (ko) 2020-12-10 2024-01-12 서울대학교산학협력단 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법
BR112023014973A2 (pt) 2021-01-27 2023-11-07 Vandria Sa Derivados de urolitina e métodos de uso dos mesmos
CN112716938A (zh) * 2021-02-25 2021-04-30 新疆医科大学 鞣花酸在制备缓解眼组织病变的药物中的用途
KR102677423B1 (ko) * 2021-09-17 2024-06-21 조선대학교산학협력단 망기페린을 포함하는 자가포식 활성화용 조성물
KR102690860B1 (ko) * 2021-10-13 2024-08-05 한국해양과학기술원 남극 진균 균주 Pleosporales sp. SF-7343 유래 대사화합물을 포함하는 염증질환 예방 또는 치료용 조성물
WO2023073079A1 (en) * 2021-10-28 2023-05-04 Société des Produits Nestlé S.A. Compositions and methods using a combination of nutrients to support cognition and emotional health in a mammal
WO2023161453A1 (en) 2022-02-24 2023-08-31 Amazentis Sa Uses of urolithins
US20230301890A1 (en) 2022-03-22 2023-09-28 Amazentis Sa Compositions comprising urolithins
WO2023237926A2 (en) * 2022-06-06 2023-12-14 Amazentis Sa Urolithins for improving cardiac function and health
WO2024025953A2 (en) * 2022-07-27 2024-02-01 Vandria Sa Therapeutic uses of urolithin derivatives
CN115433151A (zh) * 2022-09-02 2022-12-06 苏州大学 一种6，7，8-三羟基香豆素的制备方法
CN115581689B (zh) * 2022-10-17 2024-05-14 常州大学 尿石素b酰胺类衍生物的应用
GB202219317D0 (en) 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
CN117771237B (zh) * 2024-02-27 2024-05-03 南昌医学院 一种松香烷型二萜化合物的用途和制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6479103A (en) 1987-06-09 1989-03-24 Lion Corp External preparation
CA2338638C (en) 1998-07-30 2009-03-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US6440436B1 (en) 2001-05-18 2002-08-27 Natreon Inc. Process for preparing purified shilajit composition from native shilajit
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
US20060257337A1 (en) 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
EP1996021B1 (en) 2006-02-28 2017-12-13 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
WO2007127263A2 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Therapeutic uses of urolithins
US8894993B2 (en) 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
EP2155154A2 (fr) * 2007-05-11 2010-02-24 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
TW200929211A (en) 2007-12-17 2009-07-01 Etron Technology Inc Method of reducing current of memory in self-refreshing mode
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110021618A1 (en) 2008-03-25 2011-01-27 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
JP5385686B2 (ja) 2009-06-05 2014-01-08 サントリーホールディングス株式会社 血小板凝集抑制剤
CN102762573B (zh) * 2009-07-24 2015-09-16 阿马曾提斯公司 用于在神经退行性障碍中保护脑部健康的化合物、组合物和方法
RU2606763C2 (ru) * 2010-12-23 2017-01-10 Амазентис Са Композиции и способы для усиления или поддержания мышечной деятельности
US20130324595A1 (en) 2011-02-22 2013-12-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection
SG11201408539UA (en) 2012-06-27 2015-01-29 Amazentis Sa Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
EP3393467B1 (en) 2015-12-24 2020-07-01 Amazentis SA Compositions comprising nicotinamide riboside and a urolithin

Also Published As

Publication number Publication date
AU2022200876B2 (en) 2024-08-15
JP7339296B2 (ja) 2023-09-05
MX2020008468A (es) 2022-06-14
CN110934863A (zh) 2020-03-31
AU2022200876A1 (en) 2022-03-03
JP2018184455A (ja) 2018-11-22
MX2022007264A (es) 2022-07-13
US20230233523A1 (en) 2023-07-27
AU2018202407B2 (en) 2019-11-21
AU2018202407A1 (en) 2018-04-26
JP2023107934A (ja) 2023-08-03
EP2866804A2 (en) 2015-05-06
KR20230116091A (ko) 2023-08-03
WO2014004902A3 (en) 2014-03-06
MX2014016044A (es) 2015-05-12
KR102317160B1 (ko) 2021-10-25
US20200397748A1 (en) 2020-12-24
US20210353591A1 (en) 2021-11-18
AU2013284419A1 (en) 2015-02-12
US20180015069A1 (en) 2018-01-18
US9962366B2 (en) 2018-05-08
EP4233858A1 (en) 2023-08-30
CN105142632B (zh) 2020-01-07
ES2968368T3 (es) 2024-05-09
KR20200116176A (ko) 2020-10-08
US11020373B2 (en) 2021-06-01
CA2877718C (en) 2021-10-12
BR112014032809A2 (pt) 2017-06-27
AU2020200420A1 (en) 2020-03-05
SG10201610798QA (en) 2017-02-27
EP2866804B1 (en) 2023-09-13
US20160000753A1 (en) 2016-01-07
AR091604A1 (es) 2015-02-18
PT2866804T (pt) 2023-12-18
KR102163091B1 (ko) 2020-10-08
CA2877718A1 (en) 2014-01-03
US20140018415A1 (en) 2014-01-16
KR20210128511A (ko) 2021-10-26
WO2014004902A2 (en) 2014-01-03
JP6422163B2 (ja) 2018-11-14
KR20150036224A (ko) 2015-04-07
AU2020200420B2 (en) 2021-11-11
SG10202106329TA (en) 2021-07-29
JP2021119180A (ja) 2021-08-12
CA3127211A1 (en) 2014-01-03
JP2015523362A (ja) 2015-08-13
BR112014032809A8 (pt) 2021-06-22
US20230390238A1 (en) 2023-12-07
CN105142632A (zh) 2015-12-09
AU2018200791B2 (en) 2019-10-31
US11931335B2 (en) 2024-03-19
US11931336B2 (en) 2024-03-19
JP6879980B2 (ja) 2021-06-02
AU2018200791A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
SG11201408539UA (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201408261UA (en) Syringe
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201408094YA (en) Neprilysin inhibitors
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201406888QA (en) Lysin-glutamic acid dipeptide derivatives
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201408739VA (en) Inhibitors of hepatitis c virus
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201407326XA (en) Compositions and methods for treatment of mucositis
SG11201407596TA (en) Conjugation reagents
SG11201806485RA (en) Pyrrolobenzodiazepine conjugates
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
SG11201408641UA (en) Phenoxyethyl piperidine compounds